Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2016

View Archived Issues

Adjuvanted rabies vaccine from Yisheng Biopharma given U.S. orphan drug status for HCC

Advaxis initiates phase III trial of ADXS-11-001 in high-risk locally advanced cervical cancer

Celgene initiates first-in-human study of CC-90009 in relapsed or refractory AML

Imago initiates phase I trial of IMG-7289 in patients with advanced myeloid malignancies

Apitope regains global rights to ATX-MS-1467 from Merck KGaA

Omeros reports phase II data for OMS-721, pursuing FDA breakthrough therapy designation

Pfizer to begin shipping Inflectra next month

89Zr-Girentuximab imaging evaluated in first-in-human renal cell carcinoma study

Addex Therapeutics to initiate phase IIa trial of dipraglurant in focal cervical dystonia

European Commission approves Onivyde

Envisia Therapeutics releases interim data from ENV-515 phase II trial

EMA gives orphan drug designation to Eiger's exendin 9-39

FDA accepts NDA resubmission for sodium zirconium cyclosilicate

Positive opinion handed down in E.U. for SomaKit TOC

Responses seen with cabozantinib plus nivolumab in patients with genitourinary tumors

Sichuan Haisco Pharmaceutical patents M3 receptor antagonists and/or beta2-adrenoceptor agonists

Mutabilis discloses beta-lactamase inhibitors

Takeda Pharmaceutical describes MGL inhibitors

Jubilant Biosys develops HUNK1 inhibitors

Toray Industries presents kappa-opioid agonists

Regeneron and Teva update status of fasinumab programs

MYH7 mutations may be involved in nemaline myopathies with cardiomyopathy

PTC Therapeutics offers U.S. and E.U. regulatory update on Translarna

RYR3 variants may cause nemaline myopathy and fiber type disproportion

Zynerba offers updates on lead programs ZYN-001 and ZYN-002

Brain imaging successful with [11C]CB-184 in healthy human subjects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...